Although vaccines are necessary to stop transmission of SARS-CoV-2, they are not universally effective and not beneficial for already infected people. Therapeutic antibodies can fill this gap to efficiently combat SARS-CoV-2. Obviously, long-lasting efficacy of such an anti-viral approach heavily depends on the ability to protect against emerging virus variants.
As a multi-targeting strategy reduces the risk of mutagenic escape, IPA isolated a diversified pool of anti-spike protein antibodies, leveraging their proprietary antibody discovery technologies, to finally formulate a sensible therapeutic cocktail. Comprehensive, high-throughput in vitro characterization of the obtained lead candidate pool facilitated early identification of several synergistic multi-antibody cocktails, hitting non-overlapping spike protein epitopes.
Apart from unlocking synergistic effects by rationally combined antibody cocktails to boost potency, the broad spike protein epitope coverage of IPA’s diversified lead antibody pool, allows easy adaptation of the cocktails, thereby strengthening IPA’s pandemic preparedness to address current and emerging variants of SARS-CoV-2.
Spreker: Ilse Roodink, ImmunoPrecise Antibodies
Dit webinar vindt plaats op donderdag 22 april om 13:00 uur